This webinar will outline the current state of the art in the application of continuous crystallisation technologies to isolate, purify and engineer relevant  properties of active pharmaceutical ingredients (APIs) such as particle size distribution, morphology and polymorphic form of small molecule drugs with specific reference to how the process dynamics of continuous crystallisers can control and lead to a wider choice of critical product attributes for APIs than when only batch crystallisation and isolation options are considered.